Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The trend from drugs of value to medications of convenience

Doctor Grumpy, MD
Meds
May 2, 2011
Share
Tweet
Share

Pharmaceuticals are amazing stuff. You can bitch and moan about their costs, side effects, or the number of them you’re taking, but what they’ve done to extend life and improve its quality is truly remarkable.

And for all the bad raps they get, I salute the pharmaceutical industry, and those who work anonymously in labs around the world, to bring us these miracles.

But drug companies also do absolutely weird crap. One thing that’s recently driven me nuts is the trend away from drugs of real value toward what I call “drugs of convenience” (DoC).

What is a DoC? Let’s take “Sukitol.” Sukitol is dosed twice-a-day. Taking a pill twice-a-day is something most of us can remember to do. Sukitol costs, say, $2 a pill. So a month of Sukitol is $120 (these numbers are just for example, obviously).

But, like all drugs, Sukitol’s patent is going to expire. Then it will become a cheap generic (sukazolamide), and the price will drop to $0.20 per pill. So a month will now cost $12.

About 3 months before the generic comes out, the Sukitol rep shows up at my door. He now carries once-daily Sukitol-ER! Yes, now you only need to take Sukitol-ER once-a-day! And they trumpet this like it’s a major freakin’ medical breakthrough.

And they no longer carry plain old Sukitol samples. So if I want to start someone on Sukitol, I need to use Sukitol-ER, and when it goes generic in a few months, the patient ain’t gonna want twice-daily sukazolamide.

Sukitol-ER is priced at $4 a pill, so a month is, again, $120.

When the generic comes out, the patient’s insurance has a choice: pay $12/month for twice-daily sukazolamide, or $120/month for Sukitol-ER. That $108 difference becomes pretty significant if there are, say, 1 million people on the drug.

Now we get into numbers. The patient’s insurance co-pay is $5/month for sukazolamide OR $40/month for Sukitol-ER. The insurance company is hoping that by putting more financial burden on the patient, he’ll decide to go with the cheap generic.

But the drug companies have a counter to this- They’ve introduced coupons, also called “co-pay cards” or “patient loyalty cards” that give the patient $40 a month off the copay. So by using these things the patient gets Sukitol-ER free, while the insurance company is still getting dinged for the rest of the cost.

Now, given my never-ending battles with insurance companies, I don’t often sympathize with them. But here I do: the patient is getting the gold mine, and the insurance is getting the shaft. And, of course, this situation increases health care costs for ALL of us, because the insurance has to raise my premiums to pay for the fact that somebody just can’t bear the thought of having to take their pill twice-a-day instead of once.

My friends who are pharmacists also hate having to deal with the reimbursement issues on the co-pay cards, but that’s another story. If they want to comment on it, they’re welcome to.

ADVERTISEMENT

But the fun doesn’t end there. Let’s take a real drug: Flexeril (generic name cyclobenzaprine). This muscle relaxant came to market quite a while back, and consequently has been available as a generic for many years. It’s taken as a 10mg pill 3 times a day, and the generic is dirt cheap. Like a few pennies per pill.

So roughly 10 years ago, LONG after generic 10mg cyclobenzaprine was commonly available, some enterprising drug company actually was able to patent it AGAIN as a 5mg pill. They claimed it was less sedating at the lower dose, and therefore constituted a whole new drug.

And so it went to market as expensive Flexeril 5mg, because heaven forbid you should actually suggest a patient buy cheap generic 10mg cyclobenzaprine and break them in half!

Eventually the patent wore off on Flexeril 5mg, too, and it went generic, along with the 10mg. So what happened next? Another drug company actually re-patented it at a 7.5mg dose and renamed it Fexmid. I am not making this up.

Still another company has developed a once daily form of it called Amrix. So from 1 drug we now have 4 freakin’ patents.

Here’s another one: Doxepin is an ancient (by drug standards) antidepressant. It’s been around since the 1960’s. So it’s dirt cheap, and comes in pills of 10mg and up. BUT some pharmaceutical company, after 40 years on the market, has re-patented it as a 3mg or 6mg sleep aid called Silenor. So you can buy 30 days worth of 10mg pills at Target for $4 OR you can pay the same amount per pill for Silenor in a smaller size. Step right up and buy this bridge!

But the fun goes on! One that really chaps me is the bizarre trend of combining 2 old, cheap generics (some of which are even available over-the counter) to create a new, overpriced drug.

Other companies combine an existing generic with a soon-to-be generic as a desperate way of getting a few last bucks out of it. Because heaven knows it’s such a serious burden to have to take 2 pills at the same time instead of 1. This list includes Treximet (Imitrex + Naprosyn), Vimovo (Naprosyn + Nexium), Caduet (Norvasc + Lipitor), Vytorin (Zocor + Zetia), Symbyax (Prozax + Zyprexa), and many more.

No matter how much pharmaceutical companies try to portray these drugs as major medical breakthroughs, they aren’t!

I just can’t help but think that the money spent on creating them would be better spent on more novel drugs with greater long-term potential (and profit, since I admit that’s the key) to help people.

“Doctor Grumpy” is a neurologist who blogs at Doctor Grumpy in the House.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

How a model of multidisciplinary team based care may save primary care

May 2, 2011 Kevin 1
…
Next

ACP: National immigration policy and health care

May 2, 2011 Kevin 1
…

Tagged as: Medications

Post navigation

< Previous Post
How a model of multidisciplinary team based care may save primary care
Next Post >
ACP: National immigration policy and health care

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Doctor Grumpy, MD

  • Medicine can suck the compassion out of you. But I still give it my best shot.

    Doctor Grumpy, MD
  • Charging $5 per visit is easy if you’re independently wealthy

    Doctor Grumpy, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Would you refuse drugs from an Israeli drug company?

    Doctor Grumpy, MD

More in Meds

  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Functional precision oncology: a game changer in cancer therapy

    Chris Apfel, MD, PhD, MBA
  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • ER threats aren’t rare anymore—they’re routine

      Patrick Hudson, MD | Physician
    • JFK warned us about physical fitness. Sixty years later, we’re still not listening.

      Alexandre Bourcier, MD | Conditions
    • The silent threat in health care layoffs

      Todd Thorsen, MBA | Tech
    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 10 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • ER threats aren’t rare anymore—they’re routine

      Patrick Hudson, MD | Physician
    • JFK warned us about physical fitness. Sixty years later, we’re still not listening.

      Alexandre Bourcier, MD | Conditions
    • The silent threat in health care layoffs

      Todd Thorsen, MBA | Tech
    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The trend from drugs of value to medications of convenience
10 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...